MedTrace Logo

Niclosamide In Moderate COVID-19

NCT04436458 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-02-21

No results posted yet for this study

Summary

This is a Phase 2, multicentre, randomized, double blind, 2 arm placebo-controlled study in adults with moderate COVID-19 with gastrointestinal signs and symptoms.

Conditions

Interventions

DRUG

Niclosamide Oral Tablet

Continued SOC therapy together with niclosamide TID for 14 days

DRUG

Placebo

Continued SOC therapy together with placebo tablets matching niclosamide for 14 days

Sponsors & Collaborators

  • Entero Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-20
Primary Completion
2022-01-20
Completion
2022-01-20

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04436458 on ClinicalTrials.gov